



ADULT MEDICATION GUIDELINE

RALTEGRAVIR

Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Highly Restricted](#)

Medication Class

Antiretroviral – Integrase inhibitor

Presentation

Tablet: 400mg

Storage

Store at room temperature, below 30°C

Dose

HIV infection

400mg orally, 12 hourly

Post-Exposure Prophylaxis (PEP) in minors >35kg

400mg orally, 12 hourly

Total 28 day course available in SARC only

ALWAYS used in combination with at least 2 other antiretrovirals

Administration

Oral

Do not crush or chew tablets; swallow whole

Film coated tablets and chewable tablets are not bioequivalent and should not be interchanged

Monitoring

Tell your doctor immediately if you get a severe rash.

Pregnancy

1st Trimester: Monitoring required

2nd Trimester: Monitoring required

3rd Trimester: Monitoring required

Breastfeeding

This medication is contraindicated due to potential HIV transmission not based on the risk of the medication to the infant via breastmilk

Use a safe alternative method to breastfeeding to avoid postnatal HIV transmission

Comments

Tablets are not interchangeable; neither the 400 mg tablets nor the chewable tablets can be used instead of the 600 mg tablet

Raltegravir absorption is very variable

Use at least 2 other active agents in all patients to minimise development of raltegravir resistance and treatment failure (resistance to raltegravir develops easily if viral replication is not suppressed)

Related Policies, Procedures & Guidelines

HDWA Mandatory Policies:

[WA Public Health HIV/AIDS Notification](#)

WNHS Policies:

[Antimicrobial Stewardship \(AMS\) policy](#)

WNHS Clinical Practice Guidelines

References

[Post-Exposure Prophylaxis after Non-Occupational and Occupational Exposure to HIV: Australian Guidelines \(2016\)](#)









[Antiretroviral Pregnancy Register Interim report](#)

[Silver book - STI/BBV management guidelines](#)

Australian Medicines Handbook. Raltegravir. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Sep 29]. Available from: <https://amhonline.amh.net.au/>

Therapeutic Guidelines. Human immunodeficiency virus. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2021 [cited 2021 Sep 29]. Available from: <https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgAccess>

The Royal Women's Hospital Raltegravir. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Sep 29]. Available from: <https://thewomenspbmg.org.au/>

Keywords	Raltegravir, HIV, PEP, post exposure prophylaxis, blood borne virus				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	Sep 2018	Last Reviewed:	Sep 2021	Review Date:	Nov 2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	02/11/2021
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input checked="" type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.